سعر سيروكسات 20مجم 30 قرص 2026

Paroxetine 20 mg film-coated oral tablets (Seroxat, GSK), pack of 30; SSRI antidepressant.

• Most common (>=5% and at least twice placebo): abnormal ejaculation, asthenia, constipation, decreased appetite, diarrhoea, dizziness, dry mouth, female genital disorder, impotence, infection, insomnia, decreased libido, male genital disorder, nausea, nervousness, somnolence, sweating, tremor and yawning.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Use with, or within 14 days of stopping, MAOIs (including linezolid and intravenous methylene blue).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Concomitant drugs that prolong the QTc interval and are CYP2D6 substrates.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Known hypersensitivity to paroxetine or any inactive ingredient (anaphylaxis, angioedema and Stevens-Johnson syndrome reported).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: antidepressants increased the risk of suicidal thoughts and behaviours in pediatric and young adult patients; monitor all patients for clinical worsening and emergent suicidality.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Other warnings: serotonin syndrome, embryofetal toxicity, increased bleeding risk (monitor INR with warfarin), activation of mania/hypomania, discontinuation syndrome, seizures, angle-closure glaucoma, hyponatraemia and sexual dysfunction.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• MAOIs (including linezolid, IV methylene blue)Contraindicated: risk of serotonin syndrome; allow at least 14 days between stopping one and starting the other.DailyMed (U.S. National Library of Medicine)
• Warfarin and other drugs affecting haemostasis (NSAIDs, aspirin)Increased bleeding risk; monitor INR when starting, titrating or stopping paroxetine in patients on warfarin.DailyMed (U.S. National Library of Medicine)
• QTc-prolonging CYP2D6 substrates (e.g., thioridazine, pimozide)Contraindicated: paroxetine is a strong CYP2D6 inhibitor and raises their levels.DailyMed (U.S. National Library of Medicine)

• For women who intend to become pregnant or are in the first trimester, start paroxetine only after considering other treatment options. Late-pregnancy SSRI exposure carries risks of persistent pulmonary hypertension of the newborn and poor neonatal adaptation, and exposure in the month before delivery is associated with a less than 2-fold increase in postpartum haemorrhage.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Paroxetine is present in human milk (relative infant dose about 0.4-2.2%); agitation, irritability, poor feeding and poor weight gain have been reported in exposed infants, who should be monitored.International label, same formulation · DailyMed (U.S. National Library of Medicine)

English text not available for this section.